Modeling Lewy pathology propagation in Parkinson's disease
References (29)
- et al.
Staging of brain pathology related to sporadic Parkinson's disease
Neurobiol Aging
(2003) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders
Biochim Biophys Acta
(2009)- et al.
Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions
J Biol Chem
(2002) - et al.
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death
Neuron
(2011) - et al.
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein
Neuron
(2002) - et al.
Prion-like acceleration of a synucleinopathy in a transgenic mouse model
Neurobiol Aging
(2012) - et al.
Are synucleinopathies prion-like disorders?
Lancet Neurol
(2010) - et al.
Distinct alpha-synuclein strains differentially promote tau inclusions in neurons
Cell
(2013) - et al.
The neuropathology of genetic Parkinson's disease
Mov Disord
(2012) - et al.
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe
Brain
(2002)
Neuropathologic substrates of Parkinson disease dementia
Ann Neurol
A critical evaluation of the Braak staging scheme for Parkinson's disease
Ann Neurol
Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease
J Neural Transm Suppl
Evidence in favor of Braak staging of Parkinson's disease
Mov Disord
Cited by (75)
The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases
2022, Neuroscience and Biobehavioral ReviewsProgress towards therapies for disease modification in Parkinson's disease
2021, The Lancet NeurologyNeural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation
2020, Neurobiology of DiseaseCitation Excerpt :To address this hypothesis, several groups have tested the seeding and prion-like spreading of pathological αsyn in vivo (Dehay and Fernagut, 2016; Dehay et al., 2016; Rey et al., 2018b). Intracerebral or peripheral injection of recombinant αsyn fibrils or αsyn aggregates derived from brain lysates from post-mortem patients with synucleinopathy can induce αsyn aggregation in both animals overexpressing αsyn and in wild type animals (Brundin and Melki, 2017; Dehay et al., 2016; Luk and Lee, 2014; Recasens et al., 2018; Rey et al., 2018b). Several previously published studies have focused on defining the development of abnormal αsyn inclusions following injections into the striatum or in the substantia nigra, which exhibit synucleinopathy only in advanced PD.
Animal models for preclinical Parkinson's research: An update and critical appraisal
2020, Progress in Brain ResearchLewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease
2023, Journal of Neural Transmission